Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003431 · ClinicalTrials.gov registry record · Phase 1
Flt3L in Treating Patients With Metastatic Colorectal Cancer
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00003431: Completed Phase 1 study, sponsored by Duke University.
NCT00003431 is a Phase 1 study that has completed, run by Duke University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003431, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Flt3L may stimulate a person's immune system and help kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of flt3L given to patients before undergoing surgery to remove metastases from colorectal cancer.
Interventions
- BIOLOGICAL recombinant flt3 ligand
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-06 |
| Est. Completion | 2001-05 |
| Phase | Phase 1 |
What the finished NCT00003431 record still lists
NCT00003431 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which recombinant flt3 ligand is the first listed.
NCT00003431 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003431 about?
NCT00003431 is a clinical study titled "Flt3L in Treating Patients With Metastatic Colorectal Cancer". RATIONALE: Flt3L may stimulate a person's immune system and help kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of flt3L given to patients before undergoing surgery to remove metastases from colorectal cancer.
What is the current status of trial NCT00003431?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-06. Estimated completion is 2001-05.
What interventions are being tested in trial NCT00003431?
The interventions under investigation include: recombinant flt3 ligand (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003431?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia